HALT-C in the final analysis: A molehill out of a mountain

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1280-1282

  Almasio, Piero L ^a  

^a DIBIMIS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LONG TERM CARE; PRIORITY JOURNAL;

EID: 67349112883     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.03.001     Document Type: Article

References (11)

1. Almasio P., Camma C., Di Marco V., and Craxi A. Hepatitis B. In: McDonald J.W.D., et al. (Ed). Evidence-based Gastroenterology and Hepatology (2004), BMJ Books, London 367-371
2. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnù L., Mazzella G., et al. Sustained virological response to interferon-alpha is associated with improbe outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007) 579-587
3. Niederau C., Fischer R., Pürschel A., Stremmel W., Häussinger D., and Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
4. Di Bisceglie A.M., Shiffman M.L., Everson G.T., Lindsay K.L., Everhart J.E., Wright E.C., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
5. Poynard T., Moussali J., Ratziu V., Regimbeau C., and Opolon P. Effects of interferon therapy in non responder patients with chronic hepatitis C. J Hepatol 31 Suppl 1 (1999) 178-183
6. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117 (1999) 1164-1172
7. Lee W.M., Dienstag J.L., Lindsay K.L., Lok A.S., Bonkovsky H.L., Shiffman M.L., et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
8. Afdhal N.H., Levine R., Brown Jr. R., Freilich B., O'Brien M., and Brass C. Colchicine versus peginterferon alpha 2b long term therapy: results of the 4 year COPILOT trial. J Hepatol 48 Suppl 2 (2008) S4
9. Poynard T., Schiff E., Terg R., Moreno Otero R., Flamm S., Schmidt W., et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa Interferon/Ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. J Hepatol 48 Suppl 2 (2008) S369
10. Cammà C., Giunta M., Andreone P., and Craxi{dotless}̀ A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34 (2001) 593-602
11. Shiffman M.L., Morishima C., Lindsay K.L., Hoefs J.C., Dienstag J.L., Szabo G., et al. Suppression of serum HCV RNA levels during maintenance PEGINTERFERON (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial. J Hepatol 48 Suppl 2 (2008) S62